|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,410.60 INR | +1.26% |
|
-0.57% | -6.66% |
| 07-24 | Jefferies Adjusts Cipla's Price Target to INR1,170 From INR1,120, Keeps at Underperform | MT |
| 07-23 | Cipla Limited, Q1 2027 Earnings Call, Jul 23, 2026 |
Business description: Cipla Limited
Net sales by source of income break down between sale of products (96.9%) and services (3.1%).
Net sales are distributed geographically as follows: India (39.4%), the United States (18.5%), South Africa (17%) and other (25.1%).
Number of employees: 31,369
Sales by Activity: Cipla Limited
| Fiscal Period: March | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) | 2026 (INR) |
|---|---|---|---|---|---|
Pharmaceutical and Related Products | 214B | 220B | 248B | 264B | 278B |
New Ventures | 5.32B | 10.55B | 11.12B | 13.03B | - |
Inter Segment Revenue | -1.19B | -3.01B | -1.8B | -2.02B | - |
Geographical breakdown of sales: Cipla Limited
| Fiscal Period: March | 2022 (INR) | 2023 (INR) | 2024 (INR) | 2025 (INR) | 2026 (INR) |
|---|---|---|---|---|---|
India | 98.28B | 98.69B | 109B | 116B | 127B |
United States of America | 44.31B | 59.09B | 75.02B | 78.99B | 68.72B |
Rest of The World | 48.72B | 46.41B | 49.69B | 42.07B | 43.25B |
South Africa | 26.33B | 23.35B | 24.31B | 38.26B | 42.85B |
Executive Committee: Cipla Limited
| Manager | Title | Age | Since |
|---|---|---|---|
Achin Gupta
CEO | Chief Executive Officer | - | 2026-03-31 |
Sushrut Kulkarni
PSD | President | - | 2026-05-17 |
Jaideep Gogtay
CTO | Chief Tech/Sci/R&D Officer | 60 | 1994-08-31 |
| Chief Tech/Sci/R&D Officer | - | 2024-07-25 | |
Rajendra Chopra
CMP | Compliance Officer | - | 2017-02-08 |
Composition of the Board of Directors: Cipla Limited
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 90 | 1972-07-20 | |
| Director/Board Member | 72 | 2014-07-24 | |
| Director/Board Member | 71 | 2021-06-29 | |
| Director/Board Member | 50 | 2022-07-28 | |
Balram Bhargava
BRD | Director/Board Member | 65 | 2024-03-31 |
| Director/Board Member | - | 2024-08-31 | |
| Director/Board Member | 69 | 2024-09-02 | |
Maya Hari
BRD | Director/Board Member | 48 | 2024-10-31 |
Achin Gupta
BRD | Director/Board Member | - | 2026-03-31 |
Kamil Hamied
BRD | Director/Board Member | - | 2024-10-31 |
Company details: Cipla Limited
Group companies: Cipla Limited
| Name | Category and Sector |
|---|---|
Cipla BioTec Ltd.
 Cipla BioTec Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products |
Pharmaceuticals: Major
|
Meditab Specialities Pvt Ltd.
 Meditab Specialities Pvt Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products |
Pharmaceuticals: Major
|
Sitec Labs Ltd. | |
Cipla Health Ltd.
 Cipla Health Ltd. Pharmaceuticals: MajorHealth Technology Operates as a pharmaceutical company |
Pharmaceuticals: Major
|
Medispray Laboratories Pvt Ltd.
 Medispray Laboratories Pvt Ltd. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceutical products |
Pharmaceuticals: Major
|
Generic Pharmaceuticals
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.26% | -0.57% | -7.95% | +32.02% | 11.83B | |
| -0.66% | +0.44% | +14.25% | +74.56% | 48.36B | |
| +0.31% | +1.17% | +59.91% | +109.49% | 35.8B | |
| -0.46% | -3.06% | +13.55% | +78.03% | 11.48B | |
| -0.37% | -0.37% | +37.53% | +142.08% | 9.01B | |
| 0.00% | +1.59% | +47.13% | -8.60% | 6.99B | |
| -0.17% | -2.92% | +11.72% | +31.34% | 6.7B | |
| -0.59% | -1.95% | +2.18% | +171.86% | 6.42B | |
| -7.92% | -13.61% | -33.87% | -3.30% | 5.3B | |
| -2.05% | -1.46% | +21.02% | +123.76% | 4.37B | |
| Average | -1.05% | -2.05% | +16.55% | +75.12% | 14.63B | |
| Weighted average by Cap. | -0.44% | -0.48% | +24.39% | +81.07% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- CIPLA Stock
- Company Cipla Limited
Select your edition
All financial news and data tailored to specific country editions
